Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411576 | 1.00 | CYP17A1 (0.45) | CYP17A1NAMPTATRRAB9AMAP4K1 | |
| SCHEMBL22905666 | 0.89 | CYP17A1 (0.45) | CYP17A1NAMPTATRRAB9AMAP4K1 | |
| SCHEMBL30601022 | 0.87 | CYP17A1 (0.48) | CYP17A1NAMPTATRRAB9ALATS1 | |
| SCHEMBL12018154 | 0.87 | CYP17A1 (0.48) | CYP17A1NAMPTATRRAB9ALATS1 | |
| SCHEMBL6034950 | 0.83 | CYP17A1 (0.44) | CYP17A1NAMPTATRRAB9ALATS1 | |
| SCHEMBL8209502 | 0.82 | CYP17A1 (0.43) | CYP17A1NAMPTATRRAB9AIDO1 | |
| SCHEMBL18522430 | 0.81 | NAMPT (0.50) | CYP17A1NAMPTATRRAB9ALATS1 | |
| SCHEMBL23155544 | 0.79 | NAMPT (0.46) | CYP17A1NAMPTATRRAB9A | |
| SCHEMBL23674773 | 0.79 | CYP17A1 (0.48) | CYP17A1NAMPTATRRAB9ALATS1 | |
| SCHEMBL555073 | 0.79 | NAMPT (0.48) | CYP17A1NAMPTATRRAB9AMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | CYP17A1 2559/4885NAMPT 555/4885ATR 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.